An international group of around 50 nephrologists and scientists, including representatives from large dialysis provider organisations, formulated recommendations on how to develop and implement quality assurance measures to improve individual hemodialysis patient care, population health and cost effectiveness. Discussed were methods thought to be of highest priority, those clinical indicators which might be most related to meaningful patient outcomes, tools to control treatment delivery and the role of facilitating computerized expert systems. Emphasis was given to the use of new technologies such as measurement of online dialysance and ways of assessing fluid status. The current evidence linking achievement of quality criteria with patient outcomes was reviewed. This paper summarizes useful processes and quality measures supporting quality assurance that have been agreed across the expert panel. It also notes areas where more understanding is required.

1.
Dor A, Pauly MV, Eichleay MA, Held PJ: End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007;7:73-111.
2.
Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B: Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012;27(suppl 3):iii73-iii80.
3.
Canaud B: Quality control in hemodialysis: quality assurance process. Nephrologie 2000;21:403-411.
4.
Hegbrant J, Gentile G, Strippoli GFM: The quest to standardize hemodialysis care; in Ronco C, Rosner MH (eds): Hemodialysis: new methods and future technology. Contrib Nephrol. Basel, Karger, 2011, vol 171, pp 39-49.
5.
Lohr KN: Medicare: A Strategy for Quality Assurance. Washington, National Academy Press, 1990, vol I.
6.
Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC: Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 2009;119:671-679.
7.
Agarwal R: Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension 2010;56:512-517.
8.
Agarwal R: Blood pressure and mortality among hemodialysis patients. Hypertension 2010;55:62-68.
9.
Sehgal AR, Dor A, Tsai AC: Morbidity and cost implications of inadequate hemodialysis. Am J Kidney Dis 2001;37:1223-1231.
10.
O'Connor AS, Wish JB, Sehgal AR: The morbidity and cost implications of hemodialysis clinical performance measures. Hemodial Int 2005;9:349-361.
11.
Canaud B: Adequacy target in hemodialysis. J Nephrol 2004;17:77-86.
12.
Accreditation Association of Ambulatory Health Care: Clinical performance measurement. http://www.aaahc.org/en/institute/clinical-performances (accessed July 5, 2013).
13.
Viswanathan HN, Salmon W: Accrediting organizations and quality improvement. Am J Manag Care 2000;6:1117-1130.
14.
Dialysis data, once confidential, shines light on clinic disparities. http://www.propublica.org/article/dialysis-data-once-confidential-shines-light-on-clinic-disparities (accessed July 5, 2013).
15.
Williams SC, Koss RG, Morton DJ, Loeb JM: Performance of top-ranked heart care hospitals on evidence-based process measures. Circulation 2006;114:558-564.
16.
Parkerton PH, Smith DG, Belin TR, Feldbau GA: Physician performance assessment: nonequivalence of primary care measures. Med Care 2003;41:1034-1047.
17.
Kidney Disease Outcomes Quality Initiative: Hemodialysis adequacy update 2006. Am J Kidney Dis 2006;48(suppl 1):S1-S90.
18.
European Renal Association - European Dialysis and Transplant Association: European best practice guidelines for hemodialysis (part 1). Nephrol Dial Transplant 2002;17(suppl 7):1-111.
19.
Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R: EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007;22(suppl 2):ii5-ii21.
20.
Vanholder R, Abramowicz D, Cannata-Andia JB, Cocchi V, Cochat P, Covic A, Eckardt KU, Fouque D, Heimburger O, Jenkins S, MacLeod A, Lindley E, Locatelli F, London G, Monros AM, Spasovski G, Tattersall J, Van Biesen W, Wanner C, Wiecek A, Zoccali C: The future of European Nephrology ‘Guidelines' - a declaration of intent by European Renal Best Practice (ERBP). NDT Plus 2009;2:213-221.
21.
Mainz J: Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care 2003;15:523-530.
22.
Mucsi I: Health-related quality of life in chronic kidney disease patients. Prim Psychiatry 2008;15:46-51.
23.
National Institute for Health and Care Excellence: Transplantation - on dialysis. http://www.nice.org.uk/guidance/qualitystandards/chronickidneydisease/transplantationondialysis.jsp.
24.
Brown CR: Where are the patients in the quality of health care? Int J Qual Health Care 2007;19:125-126.
25.
Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, Rayner H, Saito A, Sands JS, Saran R, Gillespie B, Wolfe RA, Port FK: Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis 2009;53:475-491.
26.
Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, Held PJ: DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004;22:175-180.
27.
Mendelssohn DC, Pisoni RL, Arrington CJ, Yeates KE, Leblanc M, Deziel C, Akiba T, Krishnan M, Fukuhara S, Lameire N, Port FK, Wolfe RA: A practice-related risk score (PRS): a DOPPS-derived aggregate quality index for hemodialysis facilities. Nephrol Dial Transplant 2008;23:3227-3233.
28.
International Organization for Standardization: Water for haemodialysis and related therapies. ISO 13959:2009. http://www.iso.org/.
29.
International Organization for Standardization: Quality of dialysis fluid for haemodialysis and related therapies. ISO 11663:2009. http://www.iso.org/.
30.
International Organization for Standardization: Guidance for the preparation and quality management of fluids for haemodialysis and related therapies. ISO 23500:2011. http://www.iso.org/.
31.
Ledebo I: Clinical benefits of ultrapure dialysis fluid for hemodialysis. Hemodial Int 2007;11:S12-S17.
32.
Smart NA, Titus TT: Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med 2011;124:1073-1080.
33.
De Jager DJ, Voormolen N, Krediet RT, Dekker FE, Boeschoten EW, Grootendorst DC, and for the NECOSAD Study Group: Association between time of referral and survival in the first year of dialysis in diabetics and the elderly. Nephrol Dial Transplant 2011;26:652-658.
34.
Avorn J, Bohn RL, Levy E, Levin R, Owen WF, Winkelmayer WC, Glynn RJ: Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 2002;162:2002-2006.
35.
Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, Touam M, Nguyen AT, Grünfeld JP: Longer duration of predialysis nephrologic care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 2001;16:2357-2364.
36.
UK NHS Institute for Innovation and Improvement: http://www.institute.nhs.uk/quality_and_service_improvement_tools/quality_and_service_improvement_tools/plan_do_study_act.html (accessed July 5, 2013).
37.
Langley GL, Nolan KM, Nolan TW, Norman CL, Provost LP: The Improvement Guide: A Practical Approach to Enhancing Organizational Performance, ed 2. San Francisco, Jossey-Bass, 2009.
38.
O'Donoghue DJ: The CKD CLAHRC Collaborative: improving care for people with chronic kidney disease. Report on phase 1. Manchester, National Institute for Health Research, 2010.
39.
Humphreys J, Harvey G, Coleiro M, Butler B, Barclay A, Gwozdziewicz M, O'Donoghue D, Hegarty J: A collaborative project to improve identification and management of patients with chronic kidney disease in a primary care setting in Greater Manchester. BMJ Qual Saf 2012;21:700-708.
40.
Charytan C: Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs. Clin J Am Soc Nephrol 2010;5:2355-2362.
41.
Vanholder R, Davenport A, Hannedouche T, Kooman J, Kribben A, Lameire N, Lonneman G, Magner P, Mendelssohn D, Saggi SJ, Shaffer RN, Moe SM, Van Biesen W, van der Sande F, Mehrotra R, and on behalf of the Dialysis Advisory Group of the American Society of Nephrology: Reimbursement of dialysis: a comparison of seven countries. J Am Soc Nephrol 2012;23:1291-1298.
42.
Barth C: Quality assurance in dialysis in Germany. Dial Transplant 2010;39:404-405.
43.
McIntyre CW, Lambie SH, Taal MW, Fluck RJ: Assessment of hemodialysis adequacy by ionic dialysance: intra-patient variability of delivered treatment. Nephrol Dial Transplant 2003;18:559-563.
44.
Walters B, Pennell P, Hegbrant JBA, Nabut J, Bosch JP: The frequency of exposure to a dialysis dose of less than single-pool (sp) Kt/V of 1.2 predicts decreased survival in hemodialysis patients. Nephrol Dial Transplant 2003;18(suppl 4):170.
45.
Daugirdas JT, Tattersall JE: Automated monitoring of hemodialysis adequacy by dialysis machines: potential benefits to patients and cost savings. Kidney Int 2010;78:833-835.
46.
Mohan S, Madhrira M, Mujtaba M, Agarwala R, Pogue V, Cheng JT: Effective ionic dialysance/blood flow rate ratio: an indicator of access recirculation in arteriovenous fistulae. ASAIO J 2010;56;427-433.
47.
Tan J, Mohan S, Herbert L, Anderson H, Cheng JT: Identifying hemodialysis catheter recirculation using effective ionic dialysance. ASAIO J 2012;58:522-525.
48.
Rocco MV, Yan G, Heyka RJ, Benz R, Cheung A, and the HEMO Study Group: Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001;21:280-288.
49.
Fagugli RM, Pasini P, Quintaliani G, Pasticci F, Ciao G, Cicconi B, Ricciardi D, Santirosi PV, Buoncristiani E, Timio F, Valente F, Buoncristiani U: Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant 2003;18:2332-2338.
50.
Khosla UM, Johnson RJ: Hypertension in the hemodialysis patient and the ‘lag phenomenon': insights into pathophysiology and clinical management. Am J Kidney Dis 2004;43:739-751.
51.
Movilli E, Gaggia P, Zubani R, Camerini C, Vizzardi V, Parrinello G, Savoldi S, Fischer MS, Londrini F, Cancarini G: Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007;22:3547-3552.
52.
Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009;53:500-507.
53.
Dasselaar JJ, Huisman RM, de Jong PE, Burgerhof JGH, Franssen CFM: Effects of relative blood volume-controlled hemodialysis on blood pressure and volume status in hypertensive patients. ASAIO J 2007;53:479-484.
54.
Leunissen KM, Kouw, P, Kooman JP: New techniques to determine fluid status in hemodialyzed patients. Kidney Int 1993;41:50-56.
55.
Parfrey PS: BNP in hemodialyzed patients. Clin J Am Soc Nephrol 2010;5:954-955.
56.
Passauer J, Petrov H, Schleser A, Leicht J, Pucalka K: Evaluation of clinical dry weight assessment in hemodialysis patients using bioimpedance plethysmography: a cross-sectional study. Nephrol Dial Transplant 2010;25:545-551.
57.
Wizemann V, Rode C, Wabel P: Whole-body spectroscopy (BCM) in the assessment of normovolemia in hemodialysis patients; in Ronco C, Cruz DN (eds): Hemodialysis - from basic research to clinical trials. Contrib Nephrol. Basel, Karger, 2008, vol 161, pp 115-118.
58.
Chamney PW, Kramer M, Rode C, Kleinekofort W, Wizemann V: A new technique for establishing dry weight in hemodialysis patients via whole-body bioimpedance. Kidney Int 2002;61:2250-2258.
59.
Carmine Zoccali C, Torino C, Tripepi R, Tripepi G, D'Arrigo G, Postorino M, Gargani L, Sicari R, Picano E, Mallamaci F, and on behalf of the Lung US in CKD Working Group: Pulmonary congestion predicts cardiac events and mortality in ESRD. J Am Soc Nephrol 2013;24:639-646.
60.
Agarwal R, Kelley K, Light RP: Diagnostic utility of blood volume monitoring in hemodialysis patients. Am J Kidney Dis 2008;51:242-254.
61.
Rodriguez HJ, Domenici R, Diroll A, Goykhman I: Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney Int 2005;68:854-861.
62.
Tislér A, Akósci K, Borbás B, Fazakas L, Ferenczi S, Görögh S, Kulcsár I, Nagy L, Sámik J, Szegedi J, Tóth E, Wágner G, Kiss I: The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant 2003;18:2601-2605.
63.
Duman D, Demirtunc RE, Bulent SGM, Karadag B: Dialysis-induced hypotension is associated with impaired aortic elasticity in patients undergoing chronic hemodialysis. Blood Press Monit 2008;13:73-78.
64.
Saran R, Bragg-Gresham JL, Levin NW, et al: Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006;69:1222-1228.
65.
Santoro A, Mancini E, Basile C, Amoroso L, Di Guiglio S, Usberti M, Colasanti G, Verzetti G, Rocco A, Imbasciati E, Panzetta G, Bolzani R, Grandi F, Polacchini M: Blood volume controlled hemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial. Kidney Int 2002;62:1034-1045.
66.
Maggiore Q, Pizzarelli F, Santoro A, Panzetta G, Bonforte G, Hannedouche T, Alvarez de Lara MA, Tsouras I, Loureiro A, Ponce P, Sulkovà S, Van Roost G, Brink H, Kwan JT; Study Group of Thermal Balance and Vascular Stability: The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 2002;40:280-290.
67.
Petitclerk T, Trombert JC, Coevoet B, Jacobs C: Electrolyte modelling: is dialysate sodium profiling actually useful? Nephrol Dial Transplant 1996;11(suppl 2):35-38.
68.
Locatelli F, Altieri P, Andrulli S, Bolasco P, Sau G, Pedrini LA, Basile C, David S, Feriani M, Montagna G, Di Iorio BR, Memoli B, Cravero R, Battaglia G, Zoccali C: Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010;21:1798-1807.
69.
Plantinga LC, Fink NE, Jaar BG, Sadler JH, Levin NW, Coresh J, Klag MJ, Powe NR: Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study. BMC Health Services Res 2007;7:5.
70.
Saudan P, Kossovsky M, Halabi G, Martin PY, Perneger TV: Quality of care and survival of haemodialysed patients in western Switzerland. Nephrol Dial Transplant 2008;23:1975-1981.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.